Bengaluru: Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it anticipates a hit from a strong dollar. The company expects ...

RBC Capital analyst Shagun Singh lowered the firm’s price target on Zimmer Biomet (ZBH) to $125 from $130 but keeps an Outperform rating on the shares. The company delivered Q4 results that ...

Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Biomet fourth quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded ...

What’s going on here? Zimmer Biomet reports strong fourth-quarter results, but sees challenges ahead due to a strong US dollar and recent acquisitions. Investors are keeping a close eye on how Zimmer ...

(1) Includes inventory and manufacturing-related charges; intangible asset amortization; restructuring and other cost reduction initiatives; acquisition, integration, divestiture and related; ...

Zimmer Biomet posted Q4 adjusted EPS of $2.31, surpassing estimates, with sales of $2.02B, driven by strong knee and hip product growth. The company expects FY25 adjusted EPS of $8.15-$8.35 ...

On Thursday, Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the Street estimates of $2.30. The orthopedic giant reported ...

(RTTNews) - Zimmer Biomet Holdings Inc. (ZBH) announced a profit for fourth quarter that decreased from the same period last year but beat the Street estimates. The company's earnings totaled $239 ...

Smart Investor: Why the Bond Selloff May Be Good News, Will the Fed Still Cut Rates, and What’s Next for the AI Trade. We wrap up our coverage of the markets and the week. We sell different ...

(Reuters) - Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it anticipates a hit from a strong dollar. The company expects ...